EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MAPK-interacting kinases inhibition by eFT508 overcomes chemoresistance in preclinical model of osteosarcoma

Bin Huang, Peicheng Jin, Kaijun Yi, Junhu Duan iD

Human & Experimental Toxicology · 2023

DOI: 10.1177/09603271231158047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human & Experimental Toxicology, 2023. Verfasst von Bin Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Xiangyang No.1 People's Hospital, 36841Hubei University of Medicine, Xiangyang, China. Hauptthemen laut MEDLINE: Bone Neoplasms, Drug Resistance, Neoplasm, Osteosarcoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hubei University of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The MAPK-interacting kinases 1 and 2 (MNK1/2) have generated increasing interest as therapeutic targets for many cancers with little known in osteosarcoma. This study evaluated the efficacy of eFT508, a highly selective inhibitor of MNK1/2, as single drug alone and in combination with paclitaxel in preclinical models of osteosarcoma. EFT508 is active against multiple osteosarcoma cell lines via inhibiting growth, survival and migration. It also demonstrates anti-osteosarcoma selectivity with much less toxicity on normal osteoblastic than osteosarcoma cells. Consistent with in vitro findings, eFT508 at non-toxic dose significantly arrested tumor growth in mice throughout the whole duration of treatment. Mechanistically, eEFT508 is highly effective in blocking eIF4E phosphorylation and eIF4E-mediated protein translation. Combination index shows that eFT508 and paclitaxel is synergistic in osteosarcoma cells. Our findings highlight the therapeutic value of MNK1/2 inhibition and suggest eFT508 as a promising candidate for the treatment of osteosarcoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsDrug Resistance, NeoplasmOsteosarcomaAnimalsMiceCell Line, TumorEukaryotic Initiation Factor-4EIntracellular Signaling Peptides and ProteinsMitogen-Activated Protein Kinase KinasesPaclitaxelPhosphorylationProtein Serine-Threonine KinasesPyridinesPyrimidines

Stichwörter der Autor:innen

MNK1/2chemotherapyeFT508osteosarcomasynergism

Substanzen

Eukaryotic Initiation Factor-4EIntracellular Signaling Peptides and ProteinsMitogen-Activated Protein Kinase KinasesPaclitaxelProtein Serine-Threonine KinasestomivosertibPyridinesPyrimidines

Autor:innen und Institutionen

  • Department of Orthopedics, Xiangyang No.1 People's Hospital, 36841Hubei University of Medicine, Xiangyang, China.

ORCID-Profile: Junhu Duan

Förderung

  • Hubei University of Medicine

Zitieren

APA

Huang, B., Jin, P., Yi, K., & Duan, J. (2023). MAPK-interacting kinases inhibition by eFT508 overcomes chemoresistance in preclinical model of osteosarcoma. Human & Experimental Toxicology. https://doi.org/10.1177/09603271231158047

Vancouver

Huang B, Jin P, Yi K, Duan J. MAPK-interacting kinases inhibition by eFT508 overcomes chemoresistance in preclinical model of osteosarcoma. Human & Experimental Toxicology. 2023. doi:10.1177/09603271231158047

BibTeX
@article{Huang2023,
  author = {Huang, Bin and Jin, Peicheng and Yi, Kaijun and Duan, Junhu},
  title = {MAPK-interacting kinases inhibition by eFT508 overcomes chemoresistance in preclinical model of osteosarcoma},
  journal = {Human & Experimental Toxicology},
  year = {2023},
  doi = {10.1177/09603271231158047}
}
Kostenlos starten →